Will organigram Holdings stock grow / rise / go up?
Apr 14, 2022 · OrganiGram has a 52-week low of $1.27 and a 52-week high of $3.52. It is one of the few cannabis companies whose shares have stayed relatively steady this year, with the stock down only 0.29% in 2022.
Who bought organigram stock?
Apr 12, 2022 · What happened. Canadian cannabis company Organigram Holdings ( OGI -3.87% ) reported its second-quarter fiscal 2022 earnings today, and investors liked what they saw. The results from the ...
Is organigram efficiently growing its dividend?
Apr 14, 2022 · OrganiGram has a 52-week low of $1.27 and a 52-week high of $3.52. It is one of the few cannabis companies whose shares have stayed relatively steady this year, with the stock down only 0.29% in 2022.
How did organigram holdings' 117% year-over-year revenue jump stack up?
Organigram Holdings Inc. Analyst Report: Curaleaf Holdings, Inc. Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in …
Is OrganiGram expected to go up?
OrganiGram Holdings Inc (NASDAQ:OGI) The 12 analysts offering 12-month price forecasts for OrganiGram Holdings Inc have a median target of 2.37, with a high estimate of 4.20 and a low estimate of 1.78. The median estimate represents a +60.08% increase from the last price of 1.48.
Is OrganiGram a good stock to buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for OrganiGram Holdings Inc. stock to perform well in the short-term.
Is OrganiGram a Buy Sell or Hold?
OrganiGram has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Should I sell OrganiGram stock?
Is OrganiGram Holdings stock A Buy? OrganiGram Holdings holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Is OrganiGram a buy Zacks?
The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Who owns OrganiGram Holdings?
Major institutions are defined as firms or individuals that exercise investment discretion, over the assets of others, in excess of $100 Million....New and Sold Out Positions.OWNER NAMED. E. SHAW & CO., INC.SHARES HELD1,305,642CHANGE (SHARES)192,942CHANGE (%)17.34%VALUE (IN 1,000S)$2,19314 more columns
Is HEXO a buy or sell?
HEXO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.
Is OrganiGram a buy right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currentl...
How has OrganiGram's stock price been impacted by COVID-19?
OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO)....
When is OrganiGram's next earnings date?
OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, April 12th 2022. View our earnings forecast for OrganiGram .
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc. (NASDAQ:OGI) announced its quarterly earnings results on Tuesday, January, 11th. The company reported ($0.03) earnings per...
What price target have analysts set for OGI?
9 Wall Street analysts have issued 12-month price objectives for OrganiGram's shares. Their forecasts range from $2.25 to $5.30. On average, they a...
Who are OrganiGram's key executives?
OrganiGram's management team includes the following people: Beena G. Goldenberg , Chief Executive Officer & Director Nathalie Batten , Vice Pres...
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include IVERIC bio (ISEE) , Ligand Pharmaceuticals (LGND) , ChemoCentryx (CCXI) , Prothena (PRTA)...
What other stocks do shareholders of OrganiGram own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB) , (CGC) ,...
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
About OrganiGram
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
Headlines
CGC: Canopy Growth vs. OrganiGram: Which Cannabis Stock Is a Better Buy? - StockNews.com
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock.
Why Canopy Growth, Hexo, and OrganiGram Are Slumping Today
Canadian marijuana stocks are reversing course Monday after last week's industrywide surge higher.
Despite Market Headwinds, Organigram Is Making Progress Toward Its Goals
Like most marijuana stocks, Organigram (NASDAQ: OGI) has underperformed the market in recent years, but in its most recent fiscal first quarter, the company showed off strong growth and a narrowing loss on the bottom line. In this episode of "Beat and Raise" recorded on Jan.
Why Marijuana Stocks Are Smoking Hot Today
Marijuana stocks are having a terrific Tuesday, with OrganiGram Holdings (NASDAQ: OGI) shares gaining 8% as of 11:35 a.m. ET, Aurora Cannabis (NASDAQ: ACB) up a strong 9%, and Hexo Corp (NASDAQ: HEXO) leading the whole pack higher with a 12.8% gain. You can thank Senate Majority Leader Chuck Schumer for that.
My 2 Top Marijuana Stock Picks for 2022
Marijuana stocks flat-out floundered in 2021. Making matters worse, the top echelon of Canadian licensed producers all badly missed their own internal financial targets throughout 2021, thanks to stiff competition, changing consumer preferences, lower profit margins, the lack of development in key foreign markets, and poor execution.
Why Tilray, Organigram, and Hexo Stocks Bounced Today
Canadian cannabis company Tilray (NASDAQ: TLRY) reported its fiscal 2022 second-quarter earnings results yesterday, and its shares soared. The company surprised investors with a profitable quarter and strong revenue growth. Today, Tilray peer Organigram Holdings (NASDAQ: OGI) also reported solid quarterly results.
OrganiGram Holdings (OGI) Q1 2022 Earnings Call Transcript
Image source: The Motley Fool. OrganiGram Holdings (NASDAQ: OGI)Q1 2022 Earnings CallJan 11, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to OrganiGram Holding Inc.
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Lack of U.S. Presence Is a Real Issue for OGI Stock
The victory of President Joe Biden coupled with a flipped Senate have reignited expectations that federal cannabis legalization is on the horizon.
The Risk-Off Sentiment Is Likely to Continue
That said, high-growth risk assets, such as various small-cap cannabis plays, have been hit hard over the past month. Risk-off sentiment appears to be taking hold in the market, dragging down some marijuana stocks and making others, including OGI stock, very volatile.
What happened
Investors seemed to be taking a "sell the rumor, buy the news" approach with Canadian cannabis company Organigram Holdings (NASDAQ: OGI) over the past couple of weeks. Its shares declined by 25% during the two weeks leading up to its fiscal fourth-quarter earnings report that came out Tuesday morning.
So what
For the period, which ended Aug. 31, Organigram reported strong improvements even compared to just the prior quarter. Its took a 7% market share in recreational cannabis in its fiscal Q4, a jump of 160 basis points over fiscal Q3. And the company expects that pattern to continue, noting that its market share had grown to 7.9% as of October.
Now what
Those market share gains helped boost its net revenue by 22% both sequentially and year over year. And the company is bringing its cost of sales down, which swung its gross margin from negative to positive. Adjusted gross margin was $3 million this quarter, compared to a loss of $700,00 in its fiscal third quarter.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
.jpg)